A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

Those results — which included multiple blowout defeats — sapped much of the outside enthusiasm for real title contention, leaving the Knicks a level below the upper crust and hovering closer ...

Whether you’re looking to create a voluminous, bouncy blow out, a sleek straight haired look or a beachy wave, the blow-dry brush is the way to go. After the very first time I trialled one of ...

The global biopharma had been evaluating ociperlimab, alongside BeiGene’s own PD-1 inhibitor Tevimbra, when compared to Merck & Co.'s megablockbuster cancer med Keytruda in patients with PD-L1 ...

NEWARK, N.J. — Call it good offense or bad defense. The Alabama Crimson Tide simply don’t care how you refer to it, as long as the ball continues to go in the basket, and it most certainly did ...

The New York Yankees showed off their new 'torpedo' bats in the Bronx on Saturday by hitting a team-record nine home runs in a 20-9 rout of the visiting Milwaukee Brewers. Aaron Judge combined ...

The Maryland Terrapins have been eliminated from the NCAA Tournament after a blowout loss to the Florida Gators in the Sweet 16. Florida defeated Maryland 87-71, advancing to the Elite 8.

Forbes contributors publish independent expert analyses and insights. I write about how bitcoin, crypto and blockchain can change the world.

Merck & Co.’s subcutaneous (SC) formulation of Keytruda has matched up to the original intravenous (IV) version on two blood concentration measurements, paving way for a potential FDA approval ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite this ...